research The management of EGFR inhibitor adverse events: a case series and treatment paradigm
Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.
Search
for
Sort by
Research
270-300 / 1000+ results 
research Cutaneous manifestations associated with immune checkpoint inhibitors
Immune checkpoint inhibitors can cause skin issues but are linked to better cancer outcomes.
research Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs
New cancer drugs often cause skin and nail problems.
research Chaperones as thermodynamic sensors
New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.
research Rash from EGFR inhibitors: Opportunities and challenges for palliation
EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
research Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
Skin side effects from cancer drugs targeting EGFR can affect treatment adherence but can be managed with antibiotics like tetracycline.
research CD34 Expression by Hair Follicle Stem Cells Is Required for Skin Tumor Development in Mice
CD34 is crucial for skin tumor development in mice.
research Correspondence
A man's skin cancer improved and some of his hair grew back after treatment with a special light therapy and a medication.
research Bee venom: a case of effectiveness on skin varicosities veins with review of its dermatological benefits
Bee venom can improve various skin conditions, including varicose veins and psoriasis, and has anti-aging benefits.
research Targeting receptor–regulator interactions
New treatments for cancer and skin disorders show promise in disrupting harmful cell interactions and promoting hair growth.
research A new way to restore tumour suppressor function
New treatments may restore cancer-blocking proteins, slow prostate cancer, identify drug targets, and potentially regrow hair.
research Recent advances in nanocarrier-loaded gels: Which drug delivery technologies against which diseases?
Nanocarrier-loaded gels improve drug delivery for cancer, skin conditions, and hair loss.
research Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors
EGFR inhibitors often cause skin problems and other side effects, but these are usually reversible and can be managed to keep patients comfortable.
research Dermatologic care for lesbian, gay, bisexual, and transgender persons
LGBT individuals have unique skin health needs, including higher STD risks and side effects from gender-affirming treatments, requiring dermatologists to offer knowledgeable and culturally competent care.
research 115 AE法による実機水車発電機軸受の診断(セッション4 評価・診断II)
KSR1 is crucial for certain skin tumor formation and could be a cancer therapy target.
research Melasma and Endocrine Disorders
Melasma is a skin condition linked to female hormones, genetics, UV exposure, and certain medications, but not to pituitary, adrenal, or thyroid diseases.
research Poster Presentations
Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.
research Cemiplimab-Induced Alopecia Areata
A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.
research Skin reactions caused by epidermal growth factor receptor inhibitors and their management
EGFR inhibitors can cause skin issues, and managing these is important for treatment success.
research Is knowledge about the genetic and epigenetic alterations in melanoma a basis for targeted therapy?
Targeting multiple pathways and understanding genetic mutations are crucial for effective melanoma therapy.
research Efficacy and safety of docetaxel in the elderly
Docetaxel is safe and works well for older people with cancer, with manageable side effects.
research Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.
research Erosive pustular dermatosis of the scalp induced by gefitinib: case and review of the literature
An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.
research Green tea in dermatology.
Green tea may help with various skin conditions and protect the skin when taken orally or applied topically, but its effectiveness is not always proven.
research Loss of TET2 Tips the Scales Toward Tumorigenesis
Loss of TET2 increases the risk of skin and oral cancer.
research Skin toxicity caused by EGFR antagonists—An autoinflammatory condition triggered by deregulated IL‐1 signaling?
Blocking EGFR can cause skin inflammation by disrupting IL-1 signaling.
research Mycosis Fungoides in Elderly Adults—A Diagnostic Challenge
Diagnosing mycosis fungoides, a rare skin cancer, is difficult in elderly adults and requires careful examination to avoid mistaking it for less serious skin conditions.
research Local heroes or villains: tissue-resident memory T cells in human health and disease
Tissue-resident memory T cells can protect against infections and cancer but may also contribute to autoimmune diseases.
research Safe Selection of Genetically Manipulated Human Primary Keratinocytes with Very High Growth Potential Using CD24
Researchers found a safe and effective way to pick genetically modified skin cells with high growth potential using CD24.
research Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma
Sorafenib after liver surgery may increase survival for some liver cancer patients.